A 36-year-old woman admitted to hospital with a 5-day history of fever and cough on February 11. On January 12, she was confirmed with COVID-19. On admission, her body temperature was 37.9 °C. White blood cell count was 4.91 × 10^9^/L and lymphocytes count was 0.81 × 10^9^/L. The patient was given antiviral therapy, including lopinavir/ritonavir (lopinavir 400 mg/ritonavir 100 mg, q12 h), arbidol (0.2 g, tid) and Lianhua Qingwen Capsule (6.0 g, tid).

A chest radiograph obtained on day 5 after the onset of symptoms showed multiple high density shadow in the lower lobe 55 and basal segment of the right lung ([Fig. 1](#fig0005){ref-type="fig"} A). A new CT scan obtained on day 10 showed lesions in the lower lobe of the right lung partially absorbed ([Fig. 1](#fig0005){ref-type="fig"}B), and a CT scan obtained on day 16 showed evolution to a mixed pattern of ground-glass opacities and consolidation ([Fig. 1](#fig0005){ref-type="fig"}C). On day 22 a CT scan shown healing of the consolidations and ground-glass opacities ([Fig. 1](#fig0005){ref-type="fig"}D). On the same day, the throat swab for 2019-nCoV RNA was negative.Figure 1

A combination of 2019-nCoV RNA tests and chest CT may be helpful for rapid identification of a new case and evaluating therapeutic effect.
